Novel blood test catches pancreatic cancer at early stages
A blood test called PAXEON demonstrated 87% accuracy in detecting stage 1 and 2 pancreatic cancer in a trial of 1,800 participants. It also identified precancerous dysplasia in over 64% of high-risk individuals. The test could enable earlier intervention for a disease with a five-year survival rate of only 13%.
The PAXEON test identifies three molecular markers associated with pancreatic malignancies, with an artificial intelligence algorithm converting these signals into a personalized risk score for each patient. This multi-marker approach differs from traditional screening methods that typically rely on imaging or single biomarkers. The trial enrolled participants across the United States, Europe, and Asia, suggesting the test's performance may hold across diverse populations.
Currently, pancreatic cancer patients often receive diagnoses only after symptoms like weight loss, abdominal pain, and blood sugar irregularities become severe, by which point the disease has frequently spread. The recent FDA approval of daraxonrasib, which extends survival by roughly six months in late-stage patients, underscores how limited treatment options remain once the cancer progresses. Early detection through PAXEON could shift the clinical paradigm toward prevention and timely intervention.
The PAXEON test could substantially alter outcomes for individuals at elevated risk of pancreatic cancer, including those with inherited predispositions or chronic pancreatitis. If validated in larger trials, it may enable earlier surgical intervention and improve survival rates that have remained stagnant for decades. However, widespread adoption would require careful consideration of cost, accessibility, and the psychological impact of risk scores on patients. The test's ability to identify precancerous conditions may also open new avenues for preventive care, though clinical integration remains years away.